The Valley Desk

NCT01718353 · Interventional trial

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Overall registry status Completed

Phase 2

Conditions Prostate Cancer Metastatic

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov